Clinical Trials for CRISPR Therapeutics

Explore 10 clinical trials worldwide

Showing 1-10 of 10 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: CRISPR Therapeutics

Clinical Trials (10)

NCT06925542
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
PHASE1Recruiting
80 participants
Started: Mar 10, 2025 · Completed: Dec 31, 2031
7 conditions1 sponsor8 locations
NCT06492304
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
PHASE1/PHASE2Recruiting
290 participants
Started: Aug 13, 2024 · Completed: Nov 30, 2030
3 conditions1 sponsor7 locations
NCT06208878
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
N/AEnrolling by invitation
70 participants
Started: Nov 22, 2023 · Completed: Aug 31, 2038
2 conditions1 sponsor22 locations
NCT05795595
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
PHASE1/PHASE2Recruiting
250 participants
Started: Mar 13, 2023 · Completed: May 31, 2030
5 conditions1 sponsor7 locations
NCT05643742
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
PHASE1/PHASE2Recruiting
120 participants
Started: Mar 10, 2023 · Completed: Feb 28, 2030
8 conditions1 sponsor6 locations
NCT05565248
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
PHASE1/PHASE2Recruiting
40 participants
Started: Jan 20, 2023 · Completed: Aug 31, 2025
7 conditions2 sponsors2 locations
NCT05356195
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
PHASE3Recruiting
15 participants
Started: May 3, 2022 · Completed: May 31, 2026
5 conditions2 sponsors6 locations
NCT05329649
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
PHASE3Recruiting
15 participants
Started: May 2, 2022 · Completed: May 31, 2026
5 conditions2 sponsors7 locations
NCT04208529
A Long-term Follow-up Study in Participants Who Received CTX001
PHASE3Enrolling by invitation
160 participants
Started: Jan 20, 2021 · Completed: Sep 30, 2039
7 conditions2 sponsors19 locations
NCT03655678
A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia
PHASE2/PHASE3Active, not recruiting
59 participants
Started: Sep 14, 2018 · Completed: Dec 8, 2025
5 conditions2 sponsors14 locations